Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

NCT: NCT06101290 · RECRUITING

NCT IDNCT06101290
StatusRECRUITING
Start Date2023-12-05
Completion2035-01-15
SponsorUniversity of California, Davis (OTHER)
First posted
Last updated

Brief Summary

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

Frequently Asked Questions

What is Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)?

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) is a clinical trial registered under NCT06101290. Current status: RECRUITING.

What is the status of NCT06101290?

The current status of NCT06101290 (Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)) is: RECRUITING.

When did Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) start?

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) started on 2023-12-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.